1023594-62-8 Usage
Description
tert-butyl(1-(2-nitrophenyl)piperidin-4-yl)carbaMate is a chemical compound with the potential to be utilized in the pharmaceutical industry. It is characterized by its unique molecular structure, which includes a tert-butyl group, a 2-nitrophenyl group, and a piperidin-4-yl carbamate moiety. tert-butyl(1-(2-nitrophenyl)piperidin-4-yl)carbaMate is of interest due to its possible applications in the development of novel therapeutic agents.
Uses
Used in Pharmaceutical Industry:
tert-butyl(1-(2-nitrophenyl)piperidin-4-yl)carbaMate is used as a reactant in the preparation of heteroaryl amides. These amides are known as PIM kinase inhibitors, which are important in the treatment of cancer. PIM kinases are a family of serine/threonine protein kinases that have been implicated in the regulation of cell survival, proliferation, and differentiation. Inhibition of PIM kinases can lead to the suppression of tumor growth and the induction of apoptosis in cancer cells, making them a promising target for cancer therapy.
The use of tert-butyl(1-(2-nitrophenyl)piperidin-4-yl)carbaMate in the synthesis of PIM kinase inhibitors highlights its potential as a valuable building block in the development of new anticancer drugs. By incorporating this compound into the structure of heteroaryl amides, researchers can explore its properties and evaluate its effectiveness in targeting PIM kinases, ultimately contributing to the advancement of cancer treatment options.
Check Digit Verification of cas no
The CAS Registry Mumber 1023594-62-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,2,3,5,9 and 4 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1023594-62:
(9*1)+(8*0)+(7*2)+(6*3)+(5*5)+(4*9)+(3*4)+(2*6)+(1*2)=128
128 % 10 = 8
So 1023594-62-8 is a valid CAS Registry Number.
1023594-62-8Relevant articles and documents
PIM KINASE INHIBITORS AND METHODS OF THEIR USE
-
Page/Page column 46, (2008/12/07)
New compounds, compositions and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase- mediated disorder, such as cancer.